Clinical Development

Brought to you by:
Graphic image of an arrow nailing the bullseye of a target
Biotech

Biohaven bounces back with phase 3 ultra-rare disease win

Biohaven linked troriluzole to a slowing of progression, setting it up to take another shot at approval with an asset that the FDA refused to review.
Nick Paul Taylor Sep 23, 2024 9:22am
Colon cancer

ESMO: Innovent links cytokine to colorectal cancer responses

Sep 18, 2024 9:53am
Market Insights Whats Driving the Shift Toward FSP Models in Clinical Development

Market Insights: What’s Driving the Shift Toward FSP Models in Clinical Development?

Oct 2, 2024 8:00am
Graphic image of an arrow nailing the bullseye of a target

Ascendis' dwarfism drug hits in phase 3, threatens BioMarin

Sep 17, 2024 9:36am
Sketch of lungs

Merck, Daiichi ADC hits goal in phase 3 lung cancer study

Sep 17, 2024 7:13am
A doctor with a graphic representation of the lungs

Boehringer's phase 3 lung fibrosis trial hits primary endpoint

Sep 16, 2024 8:30am